Skip to content

Clinical study on the efficacy and safety of systemic combined with local therapy in patients with unresectable primary liver cancer

Clinical study on the efficacy and safety of systemic combined with local therapy in patients with unresectable primary liver cancer

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2200058643
Enrollment
Unknown
Registered
2022-04-13
Start date
2022-04-15
Completion date
Unknown
Last updated
2024-01-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

primary liver cancer

Interventions

Case series:No

Sponsors

The Fifth Medical Center of Chinese PLA General Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 90 Years

Inclusion criteria

Inclusion criteria: 1. The patient is 18-90 years old; 2. Patients diagnosed as primary liver cancer according to the Guidelines for Diagnosis and Treatment of Primary Liver Cancer (2022); 3. Patients with primary liver cancer who cannot be removed after surgical consultation; 4. BCLC is divided into B or C, Child Pugh scores A or B, and ECOG PS scores 0-2; 5. Expected survival time of patients = 3 months; 6. At least one measurable lesion; 7. Patients who plan to receive systematic treatment for the first time or who have experienced tumor progression by using other systematic treatments in the past; 8. The patient voluntarily participated in this clinical study, understood and signed the informed consent form, complied with the research requirements and had good compliance.

Exclusion criteria

Exclusion criteria: 1. The patient has other malignant tumors at the same time; 2. Patients with severe coagulation dysfunction or severe thrombocytopenic purpura; 3. The patients were in the active infection period of HIV, EB virus, cytomegalovirus, syphilis, tuberculosis, etc. when they were enrolled; 4. The patient has refractory ascites or severe portal hypertension; 5. The patient has severe heart, lung, kidney and other system dysfunction; 6. There are patients who are expected to have treatment interruption or cannot be evaluated for efficacy; 7. Pregnant women.

Design outcomes

Primary

MeasureTime frame
overall survival;

Secondary

MeasureTime frame
Progression free survival;tumor response;

Countries

China

Contacts

Public ContactZhen Zeng

The Fifth Medical Center of Chinese PLA General Hospital

zengzhen1970@sina.com+86 15010540233

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 5, 2026